Compare Natera Inc. Common Stock (NTRA) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while YieldMax Universe Fund of Option Income ETFs trades at $7.33 (market cap $366.97M). The key difference: Natera Inc. Common Stock is far larger — about 155.4× YieldMax Universe Fund of Option Income ETFs's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and YieldMax Universe Fund of Option Income ETFs for 57 Days on average.
| NTRA | YMAX | |
|---|---|---|
Market Cap | $57.03B | $366.97M |
Volume | 1,131,157 | 1,249,572 |
Sector | Health | Income / Options Overlay |
52-Week High | $425.64 | $12.60 |
52-Week Low | $179.42 | $7.27 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
YMAX trades at $7.61, showing minimal daily movement with a 0.13% gain. The technical outlook is bearish with moving averages signaling weakness, though oscillators remain neutral. The fund faces fundamental challenges with declining NAV and concerns about distribution sustainability despite high yields. Recent news highlights ongoing weekly distributions but also raises questions about the fund's structure and cost efficiency.
The outlook remains cautious due to persistent NAV erosion and structural concerns. While the high distribution yield provides income, the fund's long-term viability depends on addressing principal preservation. Key risks include the sustainability of the distribution policy and stacked fee structure, requiring careful monitoring of portfolio adjustments and performance metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
